Official Sections CTRMS ISVCA IPITA IPTA ISODP IRTA IXA SPLIT TID

2013 - ISBTS 2013 Symposium


This page contains exclusive content for the member of the following sections: TTS, IXA, ITA

Oral Communications - Best Abstracts 2

19.307 - Children with Short Bowel Syndrome: Intestinal Rehabilitation versus Transplant

Presenter: Clarivet, Torres, , United States
Authors: Clarivet Torres1, Mohan Parvathi1, Sona Sehgal1,2, Artis Krystal1, Cerezo Carola1, Pennington Roshnee1, Higginbotham Karen1, Anthony Sandler2

Children with Short Bowel Syndrome: Intestinal Rehabilitation versus Transplant

Clarivet Torres1, Mohan Parvathi1, Sona Sehgal1,2, Artis Krystal1, Cerezo Carola1, Pennington Roshnee1, Higginbotham Karen1, Anthony Sandler2

1Gastroenterology, Children's National Medical Center, Washington , DC, United States; 2Pathology, Hôpital Necker-enfants malades, Paris, France; 2Surgery, Childrens National Medical Center, Washington , DC, United States

The treatment of patients with short bowel syndrome (SBS) is long term parenteral nutrition (PN), Intestinal rehabilitation (IR) or transplantation. PN has been the primary treatment for SBS patients but can be associated with severe complications. Infants with SBS have a 3-fold increase in mortality than in controls with the same underlying condition but no SBS (37.5% vs. 13.3%) [1]. IR has improved the outcomes during the last decade [2]. We reviewed the outcomes of 78 patients with SBS treated at the Intestinal Rehabilitation Program (IRP) at Childrens National Medical Center (CNMC), Washington DC, during the past 5.5 years.

Seventy eight SBS patients with 3.5 month median time of PN dependency (1-164 months) were enrolled. Median age was 5 months with a median intestinal length of 40cm. The initial median daily caloric requirements by PN were 100%. Forty eight patients (61%) had hyperbilirubinemia (mean DB of 10.2mg/dl, range: 3–32mg/dl), 20 had liver biopsies (12 portal fibrosis, 5 bridging fibrosis, 3 cirrhosis). Height, weight Z score, platelet, albumin, and bilirubin were obtained at the beginning and end of the study.

All 48 patients with hyperbilirubinemia normalized their bilirubin over a mean time of 10.4 weeks using soy bean intralipid (SBIL). Out of the 78 patients, 39 (81%) reversed their cholestasis while receiving PN, 25 patients had 28 lengthening procedures (9 Bianchi, 19 STEP), and 9 patients had ostomy in continuity due to severe bowel dysmotility. Four were listed for intestinal transplant: 2 were transplanted (one with 4cm of jejunum and the other with 10cm of jejunum), one listed patient was weaned off PN (initial DB of 12mg/dl, 10cm of bowel length and half colon), and the fourth is inactive with no signs of liver disease (initial DB 19mg/dl, 10cm of jejunum joined to his sigmoid colon s/p Bianchi). One died (cardiac anomalies).  Among the 75 remaining patients, the mean caloric requirements by PN decreased from 100% to 9% and 60 (80%) patients were weaned off PN over a median time of 4 months (1-60 months).  All laboratory parameters showed improvement (p< 0.0001). Overall survival was 98.7%.

Patients with SBS treated at CNMC reverse their cholestasis using SBIL effectively and in a shorter time compared with recent reports using Omegaven [3]. With meticulous medical/surgical management, patients with advanced liver disease can improve their liver function and nutritional parameters with the ability to discontinue PN and avoid transplantation. Our IRP at CNMC has shown one of the best survivability rates (98.7%) for patients with SBS with medical and non-transplant surgical treatment. The treatment of SBS PN-dependent patients should be based on medical and non-transplant surgical options. Intestinal transplant should only be considered when those measures fail. {figure1}


Important Disclaimer

By viewing the material on this site you understand and accept that:

  1. The opinions and statements expressed on this site reflect the views of the author or authors and do not necessarily reflect those of The Transplantation Society and/or its Sections.
  2. The hosting of material on The Transplantation Society site does not signify endorsement of this material by The Transplantation Society and/or its Sections.
  3. The material is solely for educational purposes for qualified health care professionals.
  4. The Transplantation Society and/or its Sections are not liable for any decision made or action taken based on the information contained in the material on this site.
  5. The information cannot be used as a substitute for professional care.
  6. The information does not represent a standard of care.
  7. No physician-patient relationship is being established.

Social

Contact

Staff Directory
+1-514-874-1717
This email address is being protected from spambots. You need JavaScript enabled to view it.

Address

The Transplantation Society
International Headquarters
505 Boulevard René-Lévesque Ouest
Suite 1401
Montréal, QC, H2Z 1Y7
Canada